Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo- controlled, phase 2b trial

被引:118
作者
Harrison, Stephen A. [1 ,2 ]
Frias, Juan P. [3 ]
Neff, Guy [4 ]
Abrams, Gary A. [5 ]
Lucas, K. Jean [6 ]
Sanchez, William [7 ]
Gogia, Sudhanshu [8 ]
Sheikh, Muhammed Y. [9 ]
Behling, Cynthia [10 ]
Bedossa, Pierre [11 ,12 ]
Shao, Lan [13 ]
Chan, Doreen [14 ]
Fong, Erica [14 ]
de Temple, Brittany [14 ]
Shringarpure, Reshma [14 ]
Tillman, Erik J. [14 ]
Rolph, Timothy [14 ]
Cheng, Andrew [14 ]
Yale, Kitty [14 ]
机构
[1] Univ Oxford, Dept Biol, Oxford, England
[2] Pinnacle Clin Res, San Antonio, TX USA
[3] Veloc Clin Res, Los Angeles, CA USA
[4] Covenant Metab Specialists, Sarasota, FL USA
[5] Prisma Hlth Upstate, Dept Med, Greenville, SC USA
[6] Lucas Res, Morehead City, NC USA
[7] Floridian Clin Res, Miami Lakes, FL USA
[8] Texas Digest Dis Inst, Webster, TX USA
[9] Fresno Clin Res Ctr, Fresno, CA USA
[10] Sharp Mem Hosp & Rehabil Ctr, Dept Pathol, San Diego, CA USA
[11] Liverpat, Paris, France
[12] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, England
[13] Labcorp, Stat, Burlington, NC USA
[14] AkeroTherapeutics, South San Francisco, CA 94080 USA
关键词
METABOLISM; SYSTEM;
D O I
10.1016/S2468-1253(23)00272-8
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Fibroblast growth factor 21 (FGF21) regulates metabolism and protects cells against stress. Efruxifermin is a bivalent Fc-FGF21 analogue that replicates FGF21 agonism of fibroblast growth factor receptor 1c, 2c, or 3c. The aim of this phase 2b study was to assess its efficacy and safety in patients with non-alcoholic steatohepatitis (NASH) and moderate (F2) or severe (F3) fibrosis.Methods HARMONY is a multicentre, randomised, double-blind, placebo-controlled, 96-week, phase 2b trial that was initiated at 41 clinics in the USA. Adults with biopsy-confirmed NASH, defined by a non-alcoholic fatty liver disease activity score (NAS) of 4 or higher and scores of 1 or higher in each of steatosis, ballooning, and lobular inflammation, with histological stage F2 or F3 fibrosis, were randomly assigned (1:1:1), via an interactive response system, to receive placebo or efruxifermin (28 mg or 50 mg), subcutaneously once weekly. Patients, investigators, pathologists, site stall, and the sponsor were masked to group assignments during the study. The primary endpoint was the proportion of patients with improvement in fibrosis of at least 1 stage and no worsening of NASH, based on analyses of baseline and week 24 biopsies (liver biopsy analysis set [LBAS]). A sensitivity analysis evaluated the endpoint in the full analysis set (FAS), for which patients with missing biopsies were considered non-responders. This trial is registered with ClinicalTrials.gov, NCT04767529, and is ongoing.Findings Between March 22, 2021, and Feb 7, 2022, 747 patients were assessed for eligibility and 128 patients (mean age 54 center dot 7 years [SD 10 center dot 4]; 79 [62%] female and 49 male [38%]; 118 [92%] white; and 56 [41%] Hispanic or Latino) were enrolled and randomly assigned to receive placebo (n=43), efruxifermin 28 mg (n=42; two randomised patients were not dosed because of an administrative error), or efruxifermin 50 mg (n=43). In the LBAS (n=113), eight (20%) of 41 patients in the placebo group had an improvement in fibrosis of at least 1 stage and no worsening of NASH by week 24 versus 15 (39%) of 38 patients in the efruxifermin 28 mg group (risk ratio [RR] 2 center dot 3 [95% CI 1 center dot 1-4 center dot 8]; p=0 center dot 025) and 14 (41%) of 34 patients in the efruxifermin 50 mg group (2 center dot 2 [1 center dot 0-5 center dot 0]; p=0 center dot 036). Based on the FAS (n=128), eight (19%) of 43 patients in the placebo group met this endpoint versus 15 (36%) of 42 in the efruxifermin 28 mg group (RR 2 center dot 2 [95% CI 1 center dot 0-4 center dot 8]; p=0 center dot 033) and 14 (33%) of 43 in the efruxifermin 50 mg group (1 center dot 9 [0 center dot 8-4 center dot 3]; p=0 center dot 123). The most frequent efruxifermin-related adverse events were diarrhoea (16 [40%] of 40 patients in the efruxifermin 28 mg group and 17 [40%] of 43 patients in efruxifermin 50 mg group vs eight [19%] of 43 patients in the placebo group; all events except one were grade 1-2) and nausea (11 [28%] patients in the efruxifermin 28 mg group and 18 [42%] patients in the efruxifermin 50 mg group vs ten [23%] patients in the placebo group; all grade 1-2). Five patients (two in the 28 mg group and three in the 50 mg group) discontinued due to adverse events. Serious adverse events occurred in four patients in the 50 mg group; one was defined as drug related (ulcerative esophagitis in a participant with a history of gastroosophageal reflux disease). No deaths occurred. Interpretation Efruxifermin improved liver fibrosis and resolved NASH over 24 weeks in patients with F2 or F3 fibrosis, with acceptable tolerability, supporting further assessment in phase 3 trials.
引用
收藏
页码:1080 / 1093
页数:14
相关论文
共 36 条
[21]   Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH [J].
Loomba, Rohit ;
Sanyal, Arun J. ;
Kowdley, Kris V. ;
Bhatt, Deepak L. ;
Alkhouri, Naim ;
Frias, Juan P. ;
Bedossa, Pierre ;
Harrison, Stephen A. ;
Lazas, Donald ;
Barish, Robert ;
Gottwald, Mildred D. ;
Feng, Shibao ;
Agollah, Germaine D. ;
Hartsfield, Cynthia L. ;
Mansbach, Hank ;
Margalit, Maya ;
Abdelmalek, Manal F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (11) :998-1008
[22]   An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis [J].
Luo, Yi ;
Oseini, Abdul ;
Gagnon, Robert ;
Charles, Edgar D. ;
Sidik, Kurex ;
Vincent, Robert ;
Collen, Rebeca ;
Idowu, Michael ;
Contos, Melissa J. ;
Mirshahi, Faridoddin ;
Daita, Kalyani ;
Asgharpour, Amon ;
Siddiqui, Mohammed S. ;
Jarai, Gabor ;
Rosen, Glenn ;
Christian, Rose ;
Sanyal, Arun J. .
SCIENTIFIC REPORTS, 2018, 8
[23]   Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease [J].
Mak, Anne Linde ;
Lee, Jenny ;
van Dijk, Anne-Marieke ;
Vali, Yasaman ;
Aithal, Guruprasad P. ;
Schattenberg, Joern M. ;
Anstee, Quentin M. ;
Brosnan, M. Julia ;
Zafarmand, Mohammad Hadi ;
Ramsoekh, Dewkoemar ;
Harrison, Stephen A. ;
Nieuwdorp, Max ;
Bossuyt, Patrick M. ;
Holleboom, Adriaan G. .
BIOMEDICINES, 2021, 9 (12)
[24]  
Matchett KP, 2023, bioRxiv, DOI [10.1101/2023.02.24.529873v1(preprint, DOI 10.1101/2023.02.24.529873V1(PREPRINT]
[25]   FGF21 ameliorates hepatic fibrosis by multiple mechanisms [J].
Meng, Fanrui ;
Khoso, Mir Hassan ;
Kang, Kai ;
He, Qi ;
Cao, Yukai ;
Jiang, Xinghao ;
Xiao, Wei ;
Li, Deshan .
MOLECULAR BIOLOGY REPORTS, 2021, 48 (11) :7153-7163
[26]   A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis [J].
Newsome, Philip N. ;
Buchholtz, Kristine ;
Cusi, Kenneth ;
Linder, Martin ;
Okanoue, Takeshi ;
Ratziu, Vlad ;
Sanyal, Arun J. ;
Sejling, Anne-Sophie ;
Harrison, Stephen A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12) :1113-1124
[27]   A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease [J].
Romero-Gomez, Manuel ;
Lawitz, Eric ;
Shankar, R. Ravi ;
Chaudhri, Eirum ;
Liu, Jie ;
Lam, Raymond L. H. ;
Kaufman, Keith D. ;
Engel, Samuel S. .
JOURNAL OF HEPATOLOGY, 2023, 79 (04) :888-897
[28]   Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial [J].
Sanyal, Arun ;
Charles, Edgar D. ;
Neuschwander-Tetri, Brent A. ;
Loomba, Rohit ;
Harrison, Stephen A. ;
Abdelmalek, Manal F. ;
Lawitz, Eric J. ;
Halegoua-DeMarzio, Dina ;
Kundu, Sudeep ;
Noviello, Stephanie ;
Luo, Yi ;
Christian, Rose .
LANCET, 2018, 392 (10165) :2705-2717
[29]   A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys [J].
Stanislaus, Shanaka ;
Hecht, Randy ;
Yie, Junming ;
Hager, Todd ;
Hall, Michael ;
Spahr, Chris ;
Wang, Wei ;
Weiszmann, Jennifer ;
Li, Yang ;
Deng, Liying ;
Winters, Dwight ;
Smith, Stephen ;
Zhou, Lei ;
Li, Yuesheng ;
Veniant, Murielle M. ;
Xu, Jing .
ENDOCRINOLOGY, 2017, 158 (05) :1314-1327